Teva Leapfrogs Mylan And Sandoz On Linaclotide

Settlement Permits Generic Linzess Launch In 2029

 
• By Aidan Fry

A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.

Businessmen_Leapfrog
Teva has reached a patent-litigation settlement that will allow it to leapfrog its rivals into the US linaclotide market • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin